

Arch Therapeutics, Inc. (OTCQB: ARTH)

235 Walnut Street
Suite 6
Framingham, MA 01702

Share Price	\$0.46
Volume	1.11m
Shares Outstanding	154,052,013
Market Cap	\$70.85m
52 Week High	\$0.89
52 Week Low	\$0.25

as of 05/22/2018



Company Profile

Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. Arch is developing products based on an innovative self-assembling peptide technology platform to make surgery and interventional care faster and safer for patients. Arch's flagship development stage product candidate, known as the AC5 Surgical Hemostatic Device™, is being designed to achieve hemostasis in minimally invasive and open surgical procedures and is intended to be regulated as a medical device.

Management Team

Dr. Terrence W. Norchi

President, Chief Executive Officer and Director

Richard E. Davis

Chief Financial Officer

Recent News

Tuesday, May 15, 2018 - 07:50 AM

[Arch Therapeutics to Provide Corporate Update at the 8th LD Micro Invitational on Monday, June 4, 2018](#)

Tuesday, May 08, 2018 - 07:50 AM

[Arch Therapeutics Provides Update on Study Initiation and 510\(k\)](#)

Monday, March 12, 2018 - 04:30 PM

[Arch Therapeutics Provides Update on 510\(k\)](#)

Monday, March 05, 2018 - 07:50 AM

[Arch Therapeutics to Provide Corporate Update at the 30th Annual Roth Conference on March 12, 2018](#)

Monday, February 05, 2018 - 07:50 AM

[Dermatologic Surgery Publishes Clinical Data on Arch Therapeutics' AC5™ in a Topical Application](#)

Disclaimer

Except for the historical information contained herein, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on Form 10-K and its quarterly reports on Form 10-Q. The Company does not undertake any obligation to update forward-looking statements. All trademarks and brand names are the property of their respective companies.